Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practice

27 Mar 2015

Abstract excerpt

Irinotecan is a major drug in the treatment of advanced colorectal cancer. Its active form is the SN38 metabolite, which is cleared by the biliary route after glucuronidation by uridine diphosphate-glucuronosyltransferase 1A1 (UGT1A1). UGT1A1 activity exhibits a wide intersubject variability, in part related to UGT1A1 gene polymorphisms. The present review on the impact of the deficient UGT1A1*28 variant on...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer therapeutics and mechanisms
Share to Neonatal Health and Biochemistry
Share to Neutropenia and Cancer Infections

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 25817555
DOI: 10.1111/fcp.12117

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

<i><scp>UGT</scp>1A1</i> genotype and irinotecan therapy: general review and implementation in routine practicePMID 25817555Read ↗

[Interest of UGT1A1 genotyping within digestive cancers treatment by irinotecan].Semantic proximity Read ↗

Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction between UGT1A1 and irinotecan.Semantic proximity Read ↗

Pharmacogenetics of Irinotecan Disposition and Toxicity: A ReviewSemantic proximity Read ↗

An overview of the recent progress in irinotecan pharmacogenetics.Semantic proximity Read ↗

Elucidating the role of pharmacogenetics in irinotecan efficacy and adverse events in metastatic colorectal cancer patients.Semantic proximity Read ↗

UGT1A1 genotyping: a predictor of irinotecan-associated side effects and drug efficacy?Semantic proximity Read ↗

Pharmacokinetic and Pharmacogenetic Markers of Irinotecan Toxicity.Semantic proximity Read ↗

Pre-therapeutic UGT1A1 genotyping to reduce the risk of irinotecan-induced severe toxicity: Ready for prime time.Semantic proximity Read ↗

Pharmacogenetics and irinotecan therapy.Semantic proximity Read ↗

Pharmacogenetic approach for cancer treatment-tailored medicine in practice.Semantic proximity Read ↗

Pharmacogenetics of IrinotecanSemantic proximity Read ↗

Impact of the UGT1A1*28 allele on response to irinotecan: a systematic review and meta-analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.